文迪雅之争 - Suppr

Suppr

超能文献

The Avandia debate.

作者信息

Bloomgarden Zachary T

机构信息

Division of Endocrinology, Mount Sinai School of Medicine, New York, New York, USA.

出版信息

Diabetes Care. 2007 Sep;30(9):2401-8. doi: 10.2337/dc07-zb09.

DOI:10.2337/dc07-zb09

PMID:17726191

Abstract

摘要

相似文献

The Avandia debate.

Diabetes Care. 2007 Sep;30(9):2401-8. doi: 10.2337/dc07-zb09.

The Avandia debate: an unhappy conclusion.

J Diabetes. 2010 Dec;2(4):221-2. doi: 10.1111/j.1753-0407.2010.00096.x.

Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.

Harv Heart Lett. 2007 Aug;17(12):1-2.

Heart-stopping news. The diabetes drug Avandia is under fire: what you should know. Interview by Avery Comarow.

US News World Rep. 2007 Jun 4;142(20):64.

Avandia in perspective.

US News World Rep. 2007 Oct 1;143(11):71.

Drug safety. Heart attack risk overshadows a popular diabetes therapy.

Science. 2007 Jun 15;316(5831):1550-1. doi: 10.1126/science.316.5831.1550.

Drug safety. Planned study of Avandia in doubt after FDA review.

Science. 2010 Jul 23;329(5990):375. doi: 10.1126/science.329.5990.375.

Faster publication isn't always better.

Nat Clin Pract Cardiovasc Med. 2007 Jul;4(7):345. doi: 10.1038/ncpcardio0942.

Diabetes drug safety update: Avandia and your heart.

Johns Hopkins Med Lett Health After 50. 2010 Jun;22(4):1-2, 7.

Analytical issues regarding rosiglitazone meta-analysis.

Arch Intern Med. 2011 Jan 24;171(2):179-80; author reply 180. doi: 10.1001/archinternmed.2010.508.

引用本文的文献

Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.

BMJ. 2020 Feb 5;368:l7078. doi: 10.1136/bmj.l7078.

Diabetes Drugs and Cardiovascular Safety.

Endocrinol Metab (Seoul). 2016 Jun;31(2):239-44. doi: 10.3803/EnM.2016.31.2.239. Epub 2016 Jun 10.

Diabetes treatment and cardiovascular safety.

Diabetes Care. 2011 Apr;34(4):e36-42. doi: 10.2337/dc11-0201.

Redefining the role of thiazolidinediones in the management of type 2 diabetes.

Vasc Health Risk Manag. 2009;5(1):141-51. doi: 10.2147/vhrm.s4664. Epub 2009 Apr 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The Avandia debate.

Diabetes Care. 2007 Sep;30(9):2401-8. doi: 10.2337/dc07-zb09.

The Avandia debate: an unhappy conclusion.

J Diabetes. 2010 Dec;2(4):221-2. doi: 10.1111/j.1753-0407.2010.00096.x.

Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.

Harv Heart Lett. 2007 Aug;17(12):1-2.

Heart-stopping news. The diabetes drug Avandia is under fire: what you should know. Interview by Avery Comarow.

US News World Rep. 2007 Jun 4;142(20):64.

Avandia in perspective.

US News World Rep. 2007 Oct 1;143(11):71.

Drug safety. Heart attack risk overshadows a popular diabetes therapy.

Science. 2007 Jun 15;316(5831):1550-1. doi: 10.1126/science.316.5831.1550.

Drug safety. Planned study of Avandia in doubt after FDA review.

Science. 2010 Jul 23;329(5990):375. doi: 10.1126/science.329.5990.375.

Faster publication isn't always better.

Nat Clin Pract Cardiovasc Med. 2007 Jul;4(7):345. doi: 10.1038/ncpcardio0942.

Diabetes drug safety update: Avandia and your heart.

Johns Hopkins Med Lett Health After 50. 2010 Jun;22(4):1-2, 7.

Analytical issues regarding rosiglitazone meta-analysis.

Arch Intern Med. 2011 Jan 24;171(2):179-80; author reply 180. doi: 10.1001/archinternmed.2010.508.

引用本文的文献

Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.

BMJ. 2020 Feb 5;368:l7078. doi: 10.1136/bmj.l7078.

Diabetes Drugs and Cardiovascular Safety.

Endocrinol Metab (Seoul). 2016 Jun;31(2):239-44. doi: 10.3803/EnM.2016.31.2.239. Epub 2016 Jun 10.

Diabetes treatment and cardiovascular safety.

Diabetes Care. 2011 Apr;34(4):e36-42. doi: 10.2337/dc11-0201.

Redefining the role of thiazolidinediones in the management of type 2 diabetes.

Vasc Health Risk Manag. 2009;5(1):141-51. doi: 10.2147/vhrm.s4664. Epub 2009 Apr 8.